key: cord-0990357-5u33dkj2
authors: Martínez-Martínez, María; Plata-Menchaca, Erika P.; Nuvials, Francesc X.; Roca, Oriol; Ferrer, Ricard
title: Risk factors and outcomes of ventilator-associated pneumonia in COVID-19 patients: a propensity score matched analysis
date: 2021-07-06
journal: Crit Care
DOI: 10.1186/s13054-021-03654-x
sha: 28b71218e874be52cb663994627094bc503641ec
doc_id: 990357
cord_uid: 5u33dkj2

nan

Mechanically ventilated patients with coronavirus disease (COVID-19) may be at an increased risk of developing ventilator-associated pneumonia (VAP). Our aim was to describe the clinical characteristics, risk factors, and outcomes associated with VAP in critically ill COVID-19 patients.

In this single-center cohort study, all adult patients with laboratory-confirmed COVID-19, based on the detection of viral sequences by real-time reverse-transcription polymerase chain reaction, who needed mechanical ventilation (MV) between March 1, and April 30, 2020 were included. The local ethics committee approved this study and waived the need for informed consent due to the observational nature of the study. VAP was defined according to the current American Thoracic Society/ Infectious Diseases Society of America guidelines criteria [1] . Differences between quantitative variables were assessed by Student t-test or Mann-Whitney U-test. Chi-square or Fisher´s exact tests were used to analyze categorical data. To determine which variables were independently associated with VAP, a logistic regression analysis was performed, including the variables with p < 0.1 in the univariate analysis. To assess the influence of VAP in outcomes and account for inter-group imbalances of baseline characteristics, we conducted a propensity score matching including those variables with p < 0.1 in the univariate analysis. In all cases, 1:1 matching without replacement was used with a caliper 0.2 standard deviation of logit of the propensity score and with the nearest neighbor method. In the matched cohorts, differences in the categorical variables were analyzed using McNemar's test, and differences in continuous variables were determined using paired t-test or Wilcoxon signed-rank test, as appropriate. All statistical analyses were performed using the Stata Statistical Software 14 (StataCorp 15. College Station, TX: StataCorp LP) and R, version 3.6.3 (R project for Statistical Computing, http:// www.R-proje ct. org).

Of the 353 patients admitted to the intensive care unit (ICU) during the study period, 250 (70.8%) required invasive MV (Table 1) . VAP occurred in 100 (40%) of the mechanically ventilated patients. Of these, 78 were confirmed by a positive quantitative culture and 22 were defined by clinical criteria and a purulent respiratory sample. (Table 2) . According to the results reported, VAP is a frequent complication among mechanically ventilated COVID-19 patients [2, 3] and strongly impacts outcomes. It has been reported that COVID-19 makes patients more prone to VAP, not entirely due to the increased duration of the MV [3] . Despite the 28-day mortality benefit observed with corticosteroid use [4, 5] and controversies regarding tocilizumab use [6] , both treatments were initiated prior to VAP occurrence, and often prior to ICU admission, and are independently associated with a higher risk of VAP. Limitations of the present study include its observational nature, single-center setting, and the fact that the total dose of administered steroids was not recorded. However, our findings suggest that excessive immunosuppression associated with the use of immunomodulatory drugs may facilitate VAP development in COVID-19 patients. 

Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the

Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study

Ventilatorassociated pneumonia in critically ill patients with COVID-19

Dexamethasone in hospitalized patients with Covid-19

Association between administration of systemic corticosteroids and mortality among critically Ill patients with COVID-19: a meta-analysis

Mansour MK; BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

Not applicable.

MMM was responsible for the acquisition of the data and the initial draft. EPM, FXN, OR, and RF contributed substantially to the study design, data analysis, interpretation and the writing of the manuscript. All authors approved the final version to be published and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors read and approved the final manuscript.

No funding.

The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

The local ethics committee (CEIm [Comitè d'Ètica d'Investigació amb medicaments], Vall d'Hebron Institut de Recerca, Barcelona, Spain) approved this study and waived the need for informed consent due to the observational nature of the study.

Not applicable.

MMM declares that she has no competing interests. EPM declares that she has no competing interests. FXNC has received speaker fees from MSD, Pfizer, Shionogi, and Gilead outside the submitted work. OR has received research grants and speaker fees from Hamilton Medical outside the submitted work. RF has received speaker fees from MSD, Pfizer, Shionogi, and Gilead outside the submitted work.